This week, the overall grades of three Pharmaceutical stocks are lower, according to the Portfolio Grader database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).
VIVUS Inc. (NASDAQ:VVUS) is on the decline this week, earning a D (“sell”) after receiving a C (“hold”) last week. VIVUS is a biopharmaceutical company engaged in the development and commercialization of therapeutic products for large underserved markets. VVUS also rates an F in Portfolio Grader’s specific subcategory of Equity. As of April 12, 2013, 23.9% of outstanding VIVUS Inc. shares were held short. For more information, get Portfolio Grader’s complete analysis of VVUS stock.
This week, Cempra Holdings LLC’s (NASDAQ:CEMP) rating worsens to a D from the company’s C rating a week ago. Cempra, Inc. manufactures and markets pharmaceutical products. It is a clinical-stage pharmaceutical company, which focuses on developing antibiotics to meet critical unmet medical needs in the treatment of bacterial infectious diseases, particularly respiratory tract infections and skin and skin st… The stock gets F’s in Equity and Cash Flow. To get an in-depth look at CEMP, get Portfolio Grader’s complete analysis of CEMP stock.
Corcept Therapeutics (NASDAQ:CORT) earns an F (“strong sell”) this week, moving down from last week’s grade of D (“sell”). Corcept Therapeutics engages in the discovery, development, and commercialization of drugs for the treatment of severe metabolic and psychiatric disorders. The stock gets F’s in Equity and Cash Flow. The stock price has fallen 11.4% over the past month, worse than the 1.7% increase the Nasdaq has seen over the same period of time. For a full analysis of CORT stock, visit Portfolio Grader.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.